Show simple item record

Regional vitiligo induced by imiquimod treatment for in-transit melanoma metastases

dc.contributor.authorTkachenko, Elizabeth
dc.contributor.authorLin, Jennifer Y.
dc.contributor.authorHartman, Rebecca I.
dc.date2022-08-11T08:09:53.000
dc.date.accessioned2022-08-23T16:47:14Z
dc.date.available2022-08-23T16:47:14Z
dc.date.issued2019-04-29
dc.date.submitted2019-06-17
dc.identifier.citation<p>JAAD Case Rep. 2019 Apr 29;5(5):427-429. doi: 10.1016/j.jdcr.2019.03.015. eCollection 2019 May. <a href="https://doi.org/10.1016/j.jdcr.2019.03.015">Link to article on publisher's site</a></p>
dc.identifier.issn2352-5126 (Linking)
dc.identifier.doi10.1016/j.jdcr.2019.03.015
dc.identifier.pmid31065581
dc.identifier.urihttp://hdl.handle.net/20.500.14038/41040
dc.description.abstractImiquimod is a topical immunomodulator used for the treatment of viral warts and superficial basal cell carcinoma and as an emerging therapy for lentigo maligna and cutaneous melanoma metastases. Vitiligo-like depigmentation has been described as a local adverse effect of topical imiquimod therapy for melanoma1 and at distant sites in patients treated with combination topical monobenzone-imiquimod for metastatic melanoma.2 We present a case in which topical imiquimod resulted in both the resolution of in-transit metastatic melanoma and the depigmentation of local and regional skin, suggesting a regional lymphatic effect of this localized topical treatment.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=31065581&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsThis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCT
dc.subjectcomputed tomography
dc.subjectdepigmentation
dc.subjectimiquimod
dc.subjectin-transit metastases
dc.subjectmelanoma
dc.subjectvitiligo
dc.subjectDermatology
dc.subjectHemic and Immune Systems
dc.subjectHeterocyclic Compounds
dc.subjectNeoplasms
dc.subjectPharmaceutical Preparations
dc.subjectSkin and Connective Tissue Diseases
dc.subjectTherapeutics
dc.titleRegional vitiligo induced by imiquimod treatment for in-transit melanoma metastases
dc.typeJournal Article
dc.source.journaltitleJAAD case reports
dc.source.volume5
dc.source.issue5
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=4847&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/3833
dc.identifier.contextkey14751230
refterms.dateFOA2022-08-23T16:47:14Z
html.description.abstract<p>Imiquimod is a topical immunomodulator used for the treatment of viral warts and superficial basal cell carcinoma and as an emerging therapy for lentigo maligna and cutaneous melanoma metastases. Vitiligo-like depigmentation has been described as a local adverse effect of topical imiquimod therapy for melanoma1 and at distant sites in patients treated with combination topical monobenzone-imiquimod for metastatic melanoma.2 We present a case in which topical imiquimod resulted in both the resolution of in-transit metastatic melanoma and the depigmentation of local and regional skin, suggesting a regional lymphatic effect of this localized topical treatment.</p>
dc.identifier.submissionpathoapubs/3833
dc.contributor.departmentSchool of Medicine
dc.source.pages427-429


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
1_s2.0_S2352512619301183_main.pdf
Size:
644.3Kb
Format:
PDF
Download

This item appears in the following Collection(s)

Show simple item record

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Except where otherwise noted, this item's license is described as This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).